Clinical Trial Search

Primary: Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (>25% Donor Cells at 180 Days) Following RIC Regimens in Children < 21 Years Receiving…

Primary: Measured Glomerular Filtration Rate — 51.5; 47.8 mL/min/1.73m^2

Primary: Duration of Overall Survival - Percentage of Participants With an Event — 72.2; 77.4 percentage of participants

Primary: Anesthesiologist Satisfaction With the Anesthesia Using a Numeric Analog Scale (NAS) — 9.14 scores on a scale

Primary: Percentage of Participants With a Clinical Response — 53; 44 percentage of participants

Primary: Pain Intensity Using Numeric Rating Scale — 5.12; 6.36; 6.62 units on a scale — p=0.045

Primary: The Proportion of Patients in Each Treatment Group Who Are Responders at Week 2 and Continue to be Responders at Week 5 — 57; 46 participants

Primary: Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 - 24h (AUC 0-24) Response. — 0.219; 0.217 Liters

Primary: Percentage of Responders — 83.3; 25; 50; 75 percentage of participants

Primary: Number of Participants Meeting Good Sleep Latency Criteria — 7; 6 participants — p=0.655

Primary: the Relative Increase in Meal-induced Total GLP-1 Secretion — 2591; 3959 pM x 120 min

Primary: Depressive Symptom Reduction — -6.6; -10.1 Scores on a scale — p=0.01

Primary: Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100 — 37.3 Percentage of patients developing aGVHD

Primary: Change in Interstitial Fluid Pressure (IFP) Induced by Sunitinib Monotherapy — 14.0 mm Hg — p=0.0001

Primary: The Percentage of Participants With a 50% or Greater Reduction in Seizure Frequency (Further Referred to as "Responders") in a Treatment Period Compared to the Baseline…